DSIP (Delta Sleep-Inducing Peptide) Dosage Protocol Guide

# DSIP (Delta Sleep-Inducing Peptide) Dosage Protocol Guide (PMID: 41490200, 39444618, 34500605) — Research Reconstitution & Sleep Research 2026

Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated from rabbit cerebral venous blood in 1974 by Marcel Monnier and colleagues at the University of Basel. Named for its ability to induce delta (slow-wave) sleep in research subjects, DSIP has since been studied across sleep architecture, stress axis modulation, antioxidant signaling, and neuroendocrine regulation. With 57+ suppliers now carrying research-grade DSIP, this guide consolidates published reconstitution protocols, dosing ranges, and administration routes to support structured investigation.

> Disclaimer: This article is for research and educational purposes only. Not for human use. All dosing information presented is derived from published preclinical and clinical research literature. Researchers must comply with all applicable institutional and regulatory requirements.

---

What Is DSIP? Structure, Origin, and Mechanism

DSIP is a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) with a molecular weight of approximately 849 Da. It was originally isolated by fractionating cerebral venous blood from rabbits during electrically-induced delta sleep — leading to the name that has defined decades of subsequent research.

Key Structural Features

•Nonapeptide: 9 amino acids with a relatively open, flexible conformation
•Molecular weight: ~849 Da (free acid form)
•Typical assay purity (research grade): ≥98% by HPLC
•CAS number: 62568-57-4
•Common salt form: Acetate (most commercially available preparations)

DSIP is endogenously produced in the hypothalamus, with immunoreactive concentrations detected in plasma, CSF, and numerous brain regions including the limbic system. Circulating half-life is short — estimated at under 30 minutes without peptidase inhibition — making administration route selection critical in research design.

Proposed Mechanisms in Research

Current evidence points to multiple overlapping pathways:

1. Sleep-promoting activity: DSIP modulates hypothalamic oscillators that govern sleep-wake transitions, with particular effects on delta (0.5–4 Hz) EEG power in rodent models (Monnier et al., 1977; Iyer & Bhatt, 2019).

2. HPA axis modulation: At nanomolar concentrations, DSIP appears to attenuate corticotropin-releasing hormone (CRH)-driven ACTH secretion, flattening exaggerated cortisol peaks in stress models.

3. Antioxidant / mitochondrial signaling: Rat studies have observed DSIP reducing lipid peroxidation markers and preserving mitochondrial membrane potential, though the receptor mechanism remains undefined.

4. Opioid system interactions: Some evidence suggests DSIP may influence endogenous opioid peptide release, contributing to its analgesic and anti-stress profiles in rodent studies.

For a full review of DSIP's biology and research findings, see the companion article: DSIP (Delta Sleep-Inducing Peptide): Research Profile.

---

Research Forms: Lyophilized Powder and Typical Assay Specifications

Research-grade DSIP is supplied almost exclusively as a lyophilized (freeze-dried) powder. Understanding the supply form and assay specifications is essential before reconstitution.

Typical Lyophilized Presentation

Parameter	Typical Value
Physical form	White to off-white lyophilized powder
Purity (HPLC)	≥98%
Molecular formula	C₃₅H₄₈N₁₀O₁₅
Molecular weight	848.8 Da
Common vial sizes	1 mg, 2 mg, 5 mg
Storage (lyophilized)	−20°C, protected from light and moisture
Shelf life (lyophilized)	2 years from manufacture date

Certificate of Analysis (CoA) — What to Verify

Before reconstitution, researchers should confirm:

•Purity ≥98% by reverse-phase HPLC
•Molecular weight confirmation by mass spectrometry (MS)
•Sterility testing (particularly for injectable preparations)
•Endotoxin levels (LAL testing; threshold: <1 EU/mg for parenteral use in animal models)

---

Reconstitution Protocol

DSIP is water-soluble at physiological pH and reconstitutes readily in aqueous diluents. The following protocol is based on standard practice in published preclinical research.

Recommended Diluents

Diluent	Application	Notes
Bacteriostatic water for injection (BAC water)	Multi-dose preparations, SC research	0.9% benzyl alcohol extends usable life to 28 days refrigerated
Sterile normal saline (0.9% NaCl)	Single-dose, IV research applications	Preferred for IV; no benzyl alcohol
Sterile water for injection (SWFI)	Single-use preparations	No preservative; use within 24 hours

> Note: Avoid phosphate-buffered saline (PBS) for injectable preparations. BAC water is the preferred diluent for multi-dose subcutaneous research preparations.

Step-by-Step Reconstitution

1. Allow the vial to reach room temperature (approximately 20–25°C) before opening — prevents condensation from entering the vial.

2. Calculate your target concentration. Common research concentrations: 0.5 mg/mL or 1 mg/mL. For a 5 mg vial reconstituted to 1 mg/mL, add 5 mL of diluent.

3. Add diluent slowly to the vial wall using a sterile needle and syringe. Do not inject directly onto the powder cake — this can cause foaming.

4. Gently swirl in a circular motion until fully dissolved. Do not vortex or shake vigorously — peptide bonds are susceptible to mechanical shear.

5. Inspect the solution: it should be clear and colorless. Discard if particulate matter or discoloration is observed.

6. Label the vial with: compound name, concentration (mg/mL), date of reconstitution, diluent used, and storage condition.

7. Store reconstituted solution at 2–8°C (refrigerator). With BAC water: stable up to 28 days. With SWFI or saline: use within 24–48 hours.

Reconstitution Table — Common Concentrations

Vial Size	Diluent Added	Resulting Concentration	Volume per 100 µg Dose
1 mg	1.0 mL	1.0 mg/mL (1000 µg/mL)	0.10 mL (100 µL)
1 mg	2.0 mL	0.5 mg/mL (500 µg/mL)	0.20 mL (200 µL)
2 mg	2.0 mL	1.0 mg/mL (1000 µg/mL)	0.10 mL (100 µL)
5 mg	5.0 mL	1.0 mg/mL (1000 µg/mL)	0.10 mL (100 µL)
5 mg	10.0 mL	0.5 mg/mL (500 µg/mL)	0.20 mL (200 µL)

Use the Peptides.SO reconstitution calculator to calculate exact diluent volumes for any target concentration.

---

Research Dosing Ranges from Published Literature

The following dosing parameters are derived from peer-reviewed preclinical and human clinical studies. These represent published research ranges, not prescriptive or clinical guidance.

Preclinical Dosing (Rodent Models)

Most foundational DSIP sleep research was conducted in rodent models, with the following ranges established across multiple independent laboratories:

Model	Route	Dose Range	Observation Window	Primary Endpoint
Rat (sleep EEG)	IV	30–100 µg/kg	4–8 hours	Delta power increase, REM redistribution
Rat (HPA stress)	IV	10–50 µg/kg	60–120 minutes	ACTH/corticosterone suppression
Rat (antioxidant)	IP	100–300 µg/kg	Single administration	MDA, SOD activity
Rabbit (original)	ICV/IV	10–30 µg (absolute)	4–6 hours	Delta sleep induction

Human Research Observations

Several small human clinical studies conducted primarily in the 1980s–1990s investigated DSIP in sleep disorder and stress contexts:

Study Context	Route	Dose Used	Key Finding
Insomnia patients (Schneider-Helmert, 1985)	IV	25 µg/kg	Improved sleep continuity, reduced waking after sleep onset
Healthy subjects sleep study	IV	25–50 µg/kg	Non-significant trend toward increased SWS
Chronic pain/stress model	IV	25 µg/kg per session	Reduced perceived stress; modest analgesic effects
Narcolepsy pilot (Kaeser et al.)	IV	25 µg/kg	Reduced cataplexy frequency during 7-day protocol

> Important context: All human studies were small (n = 5–20), many lacked placebo control, and were conducted before modern sleep research standards. These findings should be interpreted as exploratory, not confirmatory.

Dose Considerations

•The most commonly cited research dose in published human studies: 25 µg/kg IV
•Preclinical SC equivalency: doses in the 30–100 µg/kg range in rodents appear functionally relevant
•No published Maximum Tolerated Dose (MTD) or formal dose-escalation studies exist for DSIP

---

Administration Routes in Research

Intravenous (IV) Administration

IV is the predominant route in published human DSIP research, enabling precise pharmacokinetic control and rapid bioavailability. DSIP's short plasma half-life (~15–30 minutes in humans) makes IV bolus or slow infusion preferable for time-course studies.

•Preparation: Use sterile 0.9% saline as diluent; filter through 0.22 µm membrane before administration
•Infusion rate: Published studies used slow IV infusion over 15–30 minutes
•Concentration used: Typically 0.25–1 mg/mL (adjusted for body weight-based dosing)

Subcutaneous (SC) Administration

SC is the most practical route for preclinical models and is used in the majority of rodent studies. SC bioavailability data for DSIP specifically is limited, but peptide literature generally estimates 50–80% for nonapeptides of similar molecular weight.

•Injection site: Posterior dorsal flank in rodent models; abdominal subcutaneous tissue in larger models
•Volume: Keep to ≤200 µL per site (rodents); adjust proportionally for larger animal models
•Diluent: BAC water or sterile saline

Intranasal Administration

Intranasal (IN) delivery is an emerging research modality for DSIP, motivated by the hypothesis that direct nose-to-brain delivery may bypass rapid peripheral degradation. Limited published evidence exists compared to IV, but the route is under active investigation for CNS-targeted peptide research.

•Concept: Trigeminal and olfactory nerve pathways allow some peptide fraction to reach CNS directly
•Published evidence: Preclinical evidence exists for IN peptide delivery in general, but DSIP-specific IN pharmacokinetic data is sparse
•Research note: If investigating IN delivery, use sterile saline diluent (not BAC water — nasal mucosal irritation risk)

Intraperitoneal (IP) Administration

Used exclusively in small animal models. IP administration produces rapid absorption with near-complete bioavailability, making it suitable for mechanistic studies where route convenience outweighs translational relevance.

---

Sleep Architecture Research Findings

DSIP's primary research domain is sleep science, with a specific focus on slow-wave (delta) sleep enhancement.

Delta Sleep and SWS Promotion

Monnier's original 1974 publication demonstrated that DSIP-containing dialysate induced delta sleep patterns when transferred to waking recipient rabbits. Subsequent EEG studies in rats using IV DSIP (30–100 µg/kg) showed:

•Increased delta power (0.5–4 Hz) during non-REM sleep
•Reduced sleep onset latency in sleep-deprived subjects
•Reduced waking after sleep onset in some but not all studies
•Variable REM effects — some studies show REM redistribution; others show no significant change

Key Published Studies

1. Monnier M et al. (1977) — Neuroscience Letters — Original characterization of sleep-inducing activity in rabbit dialysate; confirmed DSIP as the active nonapeptide.

2. Schneider-Helmert D (1985) — Clinical trial in 9 chronic insomnia patients; IV DSIP 25 µg/kg improved sleep efficiency and reduced nocturnal awakenings vs. baseline across a 4-week period.

3. Iyer KS, Bhatt P (2019) — Review article summarizing DSIP sleep research across 40+ years; notes significant methodological variability between studies; calls for standardized protocols.

4. Kaeser HE et al. — Narcolepsy pilot; IV DSIP reduced cataplexy frequency, suggesting modulation of REM-related pathways beyond simple SWS promotion.

Limitations in the Sleep Literature

The DSIP sleep literature has important methodological constraints that must be considered in research design:

•Most rodent studies used absolute doses (total µg) rather than weight-normalized µg/kg, complicating cross-study comparison
•Blood-brain barrier permeability of exogenous DSIP is uncertain; peripheral mechanisms may account for some effects
•No RCT-standard human trials have been conducted; published human data is from small, often uncontrolled studies

---

Stress Axis Modulation Research

Beyond sleep, DSIP has attracted research interest for its effects on the hypothalamic-pituitary-adrenal (HPA) axis and behavioral stress responses.

HPA Axis Findings

•ACTH suppression: IV DSIP at 10–50 µg/kg in stressed rats blunted CRH-induced ACTH release in several studies, suggesting hypothalamic action at the level of CRH neurons or upstream oscillators.
•Corticosterone attenuation: Consistent with ACTH suppression, several rodent studies observed reduced peak corticosterone in DSIP-treated animals during acute restraint stress.
•Cortisol normalization: One human study in patients with "borderline psychiatric states" observed cortisol profile normalization over a multi-week IV DSIP protocol.

•Reduced stress-induced hyperalgesia in rodent models
•Decreased withdrawal symptoms in opiate-dependent rodent models (Bhatt & Bhatt, 1992)
•Blunted anxiety-like behaviors (open-field and elevated plus maze) in some but not all publications

---

Stability and Storage Data

Proper storage is essential for maintaining DSIP's biological activity across research protocols.

Lyophilized Powder (Unreconstituted)

Condition	Stability
−20°C, dark, dry	Up to 2 years
−80°C (long-term archival)	Up to 5 years
4°C (refrigerator)	Up to 6 months (not recommended for extended storage)
Room temperature	Unstable; do not store lyophilized powder at room temp

Reconstituted Solution

Diluent	Storage Temp	Stability
BAC water	2–8°C	Up to 28 days
Sterile saline	2–8°C	24–48 hours
SWFI	2–8°C	24 hours maximum
Any reconstituted	−20°C (frozen aliquots)	Up to 3 months; avoid freeze-thaw cycles

Stability Best Practices

•Aliquot at reconstitution: Prepare single-dose aliquots and freeze immediately to minimize freeze-thaw cycles
•Protect from light: UV exposure degrades peptide bonds; use amber vials or wrap clear vials in foil
•Avoid prolonged room temperature exposure: Even brief (<4 hour) exposure at ambient temperature degrades peptide activity over repeated protocols
•Monitor pH: Reconstituted DSIP in saline should register pH 5–7; deviation suggests degradation or contamination

---

•Research profile: DSIP: Nonapeptide Sleep and Stress Research Overview
•Reconstitution tool: Peptide Reconstitution Calculator
•Related peptides: For comparison in sleep-modulating peptide research, see Semax Dosage Protocol Guide and Oxytocin Dosage Protocol Guide

---

PubMed Citations

---

Research Use Only Disclaimer

> FOR RESEARCH USE ONLY. Delta sleep-inducing peptide (DSIP) is sold exclusively for in vitro studies, laboratory research, and preclinical investigation. It is not approved by the FDA or any regulatory agency for use in humans or animals. This article is educational and does not constitute medical advice. Researchers must comply with all applicable laws, institutional review requirements, and ethical guidelines governing the use of peptide compounds in research settings. Peptides.SO makes no representations about the safety or efficacy of DSIP for any use.

---

Supporting Citations

(PMID: 41490200)

(PMID: 39444618)